RedPine Medical endeavors to become a pioneering global provider of single-use endoscopes
RedPine Medical (Chinese: 瑞派医疗) announced that it had raised over CNY 100 million in the Series C funding round, which was led by Yuexiu Industrial Fund (Chinese: 越秀产业基金), with participation from Eight Roads (Chinese: 斯道资本), Guangzhou Hi-tech Investment Group (Chinese: 国聚创投), Caixin Investment (Chinese: 财鑫私募).
Proceeds will be mainly used for production capacity upgrade, product iteration and upgrade, and business development both domestically and internationally.
Founded in 2015 and headquartered in Guangzhou, RedPine Medical is a provider of single-use endoscopes focusing on the R&D and production of single-use Class III MIS devices, mainly endoscopes for urology, GI, and gynecology. It has a product portfolio covering single-use endoscopes, medical endoscope image processor, single-use endoscopy devices.
RedPine Medical's products have been sold in more than 1,000 hospitals domestically, with the key regional market share exceeding 50%. While strengthening the middle- and high-level medical market, RedPine Medical has also conducted training sessions with experts in basic hospitals to improve their treatment level and facilitate the provision of medical treatment.
RedPine Medical has been granted 16 overseas registration certificates including CE to date. Its overseas channels have covered more than 20 countries and regions such as Europe, Middle East, North America, South America and Southeast Asia.
RedPine Medical's competitors include SonoScape (Chinese: 开立医疗), NovelBeam (Chinese: 海泰新光) , and AOHUA (Chinese: 澳华内镜).